Clinical Trial Update: Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer [EARLY_Phase 1]

View source ↗

Summary

The document reports the withdrawal of a Phase 1 trial evaluating pharmacodynamic effects and predictive biomarkers of ruxolitinib in operable head and neck squ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: University of Pittsburgh | Conditions: Head and Neck Squamous Cell Carcinoma | EARLY_Phase 1 | Status: WITHDRAWN